Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies

NCT03843528 is registered in ClinicalTrials.gov with Johns Hopkins All Children's Hospital as lead sponsor.

NCT NCT03843528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03843528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies
Lead sponsor
Johns Hopkins All Children's Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 1, 2019
Completion date
October 30, 2027
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, juvenile myelomonocytic leukemia, mixed phenotype acute leukemia, myelodysplastic syndromes